josh hardman
@josh-hardman.bsky.social
full of microplastics and writing about psychedelics at psychedelicalpha.com ( @psychedelicalpha.bsky.social )
Q3 2025 Psychedelic Investor Survey Results
Today, we share topline results from the latest in our series of psychedelics investor surveys.
Explore: psychedelicalpha.com/news/psyched...
Today, we share topline results from the latest in our series of psychedelics investor surveys.
Explore: psychedelicalpha.com/news/psyched...
October 7, 2025 at 10:44 AM
Q3 2025 Psychedelic Investor Survey Results
Today, we share topline results from the latest in our series of psychedelics investor surveys.
Explore: psychedelicalpha.com/news/psyched...
Today, we share topline results from the latest in our series of psychedelics investor surveys.
Explore: psychedelicalpha.com/news/psyched...
Discover Psychedelic Alpha like never before by using our new AI search tool, trained exclusively on in-house content and data.
Use any search bar on our website to get started, or visit our dedicated webpage: psychedelicalpha.com/ai
Use any search bar on our website to get started, or visit our dedicated webpage: psychedelicalpha.com/ai
August 20, 2025 at 11:43 AM
Discover Psychedelic Alpha like never before by using our new AI search tool, trained exclusively on in-house content and data.
Use any search bar on our website to get started, or visit our dedicated webpage: psychedelicalpha.com/ai
Use any search bar on our website to get started, or visit our dedicated webpage: psychedelicalpha.com/ai
Heffter Research Institute co-founder Dr. Mark Geyer spoke with Dr. Alaina Jaster for our latest interview.
Among the topics they discussed were so-called non-hallucinogenic psychedelics.
Read more: psychedelicalpha.com/news/from-hu...
Among the topics they discussed were so-called non-hallucinogenic psychedelics.
Read more: psychedelicalpha.com/news/from-hu...
August 12, 2025 at 2:41 PM
Heffter Research Institute co-founder Dr. Mark Geyer spoke with Dr. Alaina Jaster for our latest interview.
Among the topics they discussed were so-called non-hallucinogenic psychedelics.
Read more: psychedelicalpha.com/news/from-hu...
Among the topics they discussed were so-called non-hallucinogenic psychedelics.
Read more: psychedelicalpha.com/news/from-hu...
At-Home Ketamine “Completely Irresponsible”, Says UK Expert
“In the psychedelic world, we are very aware that context is important,” Professor Celia Morgan said, referring to set and setting, as well as the social matrix surrounding the drug user.
psychedelicalpha.com/news/therapy...
“In the psychedelic world, we are very aware that context is important,” Professor Celia Morgan said, referring to set and setting, as well as the social matrix surrounding the drug user.
psychedelicalpha.com/news/therapy...
August 5, 2025 at 1:44 PM
At-Home Ketamine “Completely Irresponsible”, Says UK Expert
“In the psychedelic world, we are very aware that context is important,” Professor Celia Morgan said, referring to set and setting, as well as the social matrix surrounding the drug user.
psychedelicalpha.com/news/therapy...
“In the psychedelic world, we are very aware that context is important,” Professor Celia Morgan said, referring to set and setting, as well as the social matrix surrounding the drug user.
psychedelicalpha.com/news/therapy...
August 4, 2025 at 4:59 PM
Germany joins Switzerland in allowing certain European patients to access psilocybin when they have exhausted other options.
The imprimatur of Swiss engineering & German efficiency and process-focus could add to psychedelic medicine’s legitimacy.
More: psychedelicalpha.com/news/germany...
The imprimatur of Swiss engineering & German efficiency and process-focus could add to psychedelic medicine’s legitimacy.
More: psychedelicalpha.com/news/germany...
July 31, 2025 at 8:22 AM
Germany joins Switzerland in allowing certain European patients to access psilocybin when they have exhausted other options.
The imprimatur of Swiss engineering & German efficiency and process-focus could add to psychedelic medicine’s legitimacy.
More: psychedelicalpha.com/news/germany...
The imprimatur of Swiss engineering & German efficiency and process-focus could add to psychedelic medicine’s legitimacy.
More: psychedelicalpha.com/news/germany...
Q3 2025: Psychedelic Investor Survey
If you have invested in, or are considering investing in, a psychedelics-related company, please complete our latest Psychedelic Investor Survey.
docs.google.com/forms/d/1T_r...
If you have invested in, or are considering investing in, a psychedelics-related company, please complete our latest Psychedelic Investor Survey.
docs.google.com/forms/d/1T_r...
July 18, 2025 at 2:18 PM
Q3 2025: Psychedelic Investor Survey
If you have invested in, or are considering investing in, a psychedelics-related company, please complete our latest Psychedelic Investor Survey.
docs.google.com/forms/d/1T_r...
If you have invested in, or are considering investing in, a psychedelics-related company, please complete our latest Psychedelic Investor Survey.
docs.google.com/forms/d/1T_r...
Reconstructing Meaning: Chris Timmermann on the Neurophenomenology of Psychedelics
Read our interview with Chris Timmermann:
psychedelicalpha.com/news/reconst...
Read our interview with Chris Timmermann:
psychedelicalpha.com/news/reconst...
July 3, 2025 at 2:21 PM
Reconstructing Meaning: Chris Timmermann on the Neurophenomenology of Psychedelics
Read our interview with Chris Timmermann:
psychedelicalpha.com/news/reconst...
Read our interview with Chris Timmermann:
psychedelicalpha.com/news/reconst...
Lorde Gets Over Stage Fright with MDMA-Assisted Therapy
Speaking with Stephen Colbert on The Late Show, Kiwi singer Lorde said that MDMA-assisted therapy “truly changed the game on my stage fright.”
Speaking with Stephen Colbert on The Late Show, Kiwi singer Lorde said that MDMA-assisted therapy “truly changed the game on my stage fright.”
June 29, 2025 at 7:02 PM
Lorde Gets Over Stage Fright with MDMA-Assisted Therapy
Speaking with Stephen Colbert on The Late Show, Kiwi singer Lorde said that MDMA-assisted therapy “truly changed the game on my stage fright.”
Speaking with Stephen Colbert on The Late Show, Kiwi singer Lorde said that MDMA-assisted therapy “truly changed the game on my stage fright.”
Mike Burke is Lykos Therapeutics' new CEO.
Former FDA reviewer and (for a brief stint) MindMed VP R&D Javier Muniz joins as CMO.
Former CEO Amy Emerson joins Board.
Former FDA reviewer and (for a brief stint) MindMed VP R&D Javier Muniz joins as CMO.
Former CEO Amy Emerson joins Board.
June 28, 2025 at 6:44 PM
Mike Burke is Lykos Therapeutics' new CEO.
Former FDA reviewer and (for a brief stint) MindMed VP R&D Javier Muniz joins as CMO.
Former CEO Amy Emerson joins Board.
Former FDA reviewer and (for a brief stint) MindMed VP R&D Javier Muniz joins as CMO.
Former CEO Amy Emerson joins Board.
Compass Pathways’ Psilocybin Clears First Phase 3 Hurdle
“Rest assured, we’ve got something pretty special here”, Chief Commercial Officer Englebert told Psychedelic Alpha.
psychedelicalpha.com/news/compass...
“Rest assured, we’ve got something pretty special here”, Chief Commercial Officer Englebert told Psychedelic Alpha.
psychedelicalpha.com/news/compass...
June 23, 2025 at 10:33 AM
Compass Pathways’ Psilocybin Clears First Phase 3 Hurdle
“Rest assured, we’ve got something pretty special here”, Chief Commercial Officer Englebert told Psychedelic Alpha.
psychedelicalpha.com/news/compass...
“Rest assured, we’ve got something pretty special here”, Chief Commercial Officer Englebert told Psychedelic Alpha.
psychedelicalpha.com/news/compass...
📫 Each Sunday, we at Psychedelic Alpha send our Psychedelic News Feed to fifteen thousand psychedelics insiders.
Bookmark the live News Feed and subscribe for free to get the Sunday roundup: psychedelicalpha.com/live
🔗 Links to all the stories mentioned above can be found there, too.
Bookmark the live News Feed and subscribe for free to get the Sunday roundup: psychedelicalpha.com/live
🔗 Links to all the stories mentioned above can be found there, too.
June 3, 2025 at 1:02 PM
📫 Each Sunday, we at Psychedelic Alpha send our Psychedelic News Feed to fifteen thousand psychedelics insiders.
Bookmark the live News Feed and subscribe for free to get the Sunday roundup: psychedelicalpha.com/live
🔗 Links to all the stories mentioned above can be found there, too.
Bookmark the live News Feed and subscribe for free to get the Sunday roundup: psychedelicalpha.com/live
🔗 Links to all the stories mentioned above can be found there, too.
BREAKING: Czech Republic Set to Allow Medical Use of Psilocybin
If approved by the Senate next month, it will become the third country in the world to allow access to a psychedelic ahead of conventional marketing approval.
If approved by the Senate next month, it will become the third country in the world to allow access to a psychedelic ahead of conventional marketing approval.
May 31, 2025 at 5:20 PM
BREAKING: Czech Republic Set to Allow Medical Use of Psilocybin
If approved by the Senate next month, it will become the third country in the world to allow access to a psychedelic ahead of conventional marketing approval.
If approved by the Senate next month, it will become the third country in the world to allow access to a psychedelic ahead of conventional marketing approval.
After Controversy, the Psilocybin & Religious Leaders Study Is Finally Published
Johns Hopkins and NYU have released their research on the effects of psilocybin on religious leaders via a journal article in Psychedelic Medicine.
The study: www.liebertpub.com/doi/10.1089/...
Johns Hopkins and NYU have released their research on the effects of psilocybin on religious leaders via a journal article in Psychedelic Medicine.
The study: www.liebertpub.com/doi/10.1089/...
May 30, 2025 at 5:43 PM
After Controversy, the Psilocybin & Religious Leaders Study Is Finally Published
Johns Hopkins and NYU have released their research on the effects of psilocybin on religious leaders via a journal article in Psychedelic Medicine.
The study: www.liebertpub.com/doi/10.1089/...
Johns Hopkins and NYU have released their research on the effects of psilocybin on religious leaders via a journal article in Psychedelic Medicine.
The study: www.liebertpub.com/doi/10.1089/...
Psychedelic Alpha readers are deeply divided over what to expect from the Trump administration re: psychedelics-related reforms and action.
May 22, 2025 at 4:22 PM
Psychedelic Alpha readers are deeply divided over what to expect from the Trump administration re: psychedelics-related reforms and action.
Psychedelic Alpha Readers Cautiously Optimistic Re: Compass Pathways' Upcoming Phase 3 Readout
Last week, we asked what sort of results you're expecting from Compass’ Phase 3 psilocybin for treatment-resistant depression study readout, expected in late June.
Results:
Last week, we asked what sort of results you're expecting from Compass’ Phase 3 psilocybin for treatment-resistant depression study readout, expected in late June.
Results:
May 11, 2025 at 2:27 PM
Psychedelic Alpha Readers Cautiously Optimistic Re: Compass Pathways' Upcoming Phase 3 Readout
Last week, we asked what sort of results you're expecting from Compass’ Phase 3 psilocybin for treatment-resistant depression study readout, expected in late June.
Results:
Last week, we asked what sort of results you're expecting from Compass’ Phase 3 psilocybin for treatment-resistant depression study readout, expected in late June.
Results:
First Look at Gilgamesh Pharmaceuticals' Phase 2a Data: Psychedelic Candidate Yields Effect Size of ~1.0, But Sparse Details
Company reports an effect size of around 1.0 and no serious safety concerns. Results hint at promising efficacy.
More: psychedelicalpha.com/news/p%ce%b1...
Company reports an effect size of around 1.0 and no serious safety concerns. Results hint at promising efficacy.
More: psychedelicalpha.com/news/p%ce%b1...
May 9, 2025 at 3:18 PM
First Look at Gilgamesh Pharmaceuticals' Phase 2a Data: Psychedelic Candidate Yields Effect Size of ~1.0, But Sparse Details
Company reports an effect size of around 1.0 and no serious safety concerns. Results hint at promising efficacy.
More: psychedelicalpha.com/news/p%ce%b1...
Company reports an effect size of around 1.0 and no serious safety concerns. Results hint at promising efficacy.
More: psychedelicalpha.com/news/p%ce%b1...
Half of ASCP 2025's Pharmaceutical Pipeline Features Psychedelics
In our latest Bulletin, we review the dozens of poster and presentation abstracts to bring you a preview.
More: psychedelicalpha.com/news/p%ce%b1...
In our latest Bulletin, we review the dozens of poster and presentation abstracts to bring you a preview.
More: psychedelicalpha.com/news/p%ce%b1...
May 9, 2025 at 3:14 PM
Half of ASCP 2025's Pharmaceutical Pipeline Features Psychedelics
In our latest Bulletin, we review the dozens of poster and presentation abstracts to bring you a preview.
More: psychedelicalpha.com/news/p%ce%b1...
In our latest Bulletin, we review the dozens of poster and presentation abstracts to bring you a preview.
More: psychedelicalpha.com/news/p%ce%b1...
Otsuka Eyes Psychedelic Future in Japan with New Infrastructure Drive
Read more in Psychedelic Bulletin 196: psychedelicalpha.com/news/p%ce%b1...
Read more in Psychedelic Bulletin 196: psychedelicalpha.com/news/p%ce%b1...
May 9, 2025 at 3:11 PM
Otsuka Eyes Psychedelic Future in Japan with New Infrastructure Drive
Read more in Psychedelic Bulletin 196: psychedelicalpha.com/news/p%ce%b1...
Read more in Psychedelic Bulletin 196: psychedelicalpha.com/news/p%ce%b1...
Despite many investors holding breaths, in Q1 larger investors showed some appetite to back mid- and late-stage drug dev programs.
But virtually all of Q1’s inflows accrued to the larger publicly-traded drug developers, with almost no activity at the private company level...
But virtually all of Q1’s inflows accrued to the larger publicly-traded drug developers, with almost no activity at the private company level...
April 22, 2025 at 3:44 PM
Despite many investors holding breaths, in Q1 larger investors showed some appetite to back mid- and late-stage drug dev programs.
But virtually all of Q1’s inflows accrued to the larger publicly-traded drug developers, with almost no activity at the private company level...
But virtually all of Q1’s inflows accrued to the larger publicly-traded drug developers, with almost no activity at the private company level...
March 2025’s Psychedelic Policy Momentum: New Bills Filed Across the U.S. as Nearly 30 States Deliberate Reforms
Here, Psychedelic Alpha’s Noah Smith & I present a state-by-state, bill-by-bill round-up of psychedelics-focused bills introduced in March.
More: psychedelicalpha.com/news/march-2...
Here, Psychedelic Alpha’s Noah Smith & I present a state-by-state, bill-by-bill round-up of psychedelics-focused bills introduced in March.
More: psychedelicalpha.com/news/march-2...
April 7, 2025 at 2:35 PM
March 2025’s Psychedelic Policy Momentum: New Bills Filed Across the U.S. as Nearly 30 States Deliberate Reforms
Here, Psychedelic Alpha’s Noah Smith & I present a state-by-state, bill-by-bill round-up of psychedelics-focused bills introduced in March.
More: psychedelicalpha.com/news/march-2...
Here, Psychedelic Alpha’s Noah Smith & I present a state-by-state, bill-by-bill round-up of psychedelics-focused bills introduced in March.
More: psychedelicalpha.com/news/march-2...
We will soon launch our second new product, The Shroomberg Terminal.
Learn more and join the waitlist at the bottom of this page: psychedelicalpha.com/tripradar-by...
Learn more and join the waitlist at the bottom of this page: psychedelicalpha.com/tripradar-by...
April 1, 2025 at 3:18 PM
We will soon launch our second new product, The Shroomberg Terminal.
Learn more and join the waitlist at the bottom of this page: psychedelicalpha.com/tripradar-by...
Learn more and join the waitlist at the bottom of this page: psychedelicalpha.com/tripradar-by...
Use our TripSync feature to synchronise your experience with friends across the globe.
It's like Zwift, but for psychedelic trips.
It's like Zwift, but for psychedelic trips.
April 1, 2025 at 3:01 PM
Use our TripSync feature to synchronise your experience with friends across the globe.
It's like Zwift, but for psychedelic trips.
It's like Zwift, but for psychedelic trips.
TripRader leverages AI to generate predictive trip forecasts and proprietary insights into current and future ego death hotspots.
Looking to identify the next ego death experience in Philly, or DMT trip in Durban? We have you covered.
Looking to identify the next ego death experience in Philly, or DMT trip in Durban? We have you covered.
April 1, 2025 at 3:01 PM
TripRader leverages AI to generate predictive trip forecasts and proprietary insights into current and future ego death hotspots.
Looking to identify the next ego death experience in Philly, or DMT trip in Durban? We have you covered.
Looking to identify the next ego death experience in Philly, or DMT trip in Durban? We have you covered.
Psychedelic Alpha Launches TripRadar
I am very pleased to announce our latest product: TripRadar, which allows you to see, share, and sync with the global psychedelic experience in real time.
Our new app has several unique features...
I am very pleased to announce our latest product: TripRadar, which allows you to see, share, and sync with the global psychedelic experience in real time.
Our new app has several unique features...
April 1, 2025 at 3:01 PM
Psychedelic Alpha Launches TripRadar
I am very pleased to announce our latest product: TripRadar, which allows you to see, share, and sync with the global psychedelic experience in real time.
Our new app has several unique features...
I am very pleased to announce our latest product: TripRadar, which allows you to see, share, and sync with the global psychedelic experience in real time.
Our new app has several unique features...